Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Current Deferred Revenue (2020 - 2025)

Gain Therapeutics (GANX) has 6 years of Current Deferred Revenue data on record, last reported at $11293.0 in Q3 2025.

  • For Q3 2025, Current Deferred Revenue fell 98.41% year-over-year to $11293.0; the TTM value through Sep 2025 reached $11293.0, down 98.41%, while the annual FY2024 figure was $252211.0, 77.52% down from the prior year.
  • Current Deferred Revenue reached $11293.0 in Q3 2025 per GANX's latest filing, down from $22685.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $1.4 million in Q3 2023 and bottomed at $11293.0 in Q3 2025.
  • Average Current Deferred Revenue over 5 years is $439851.4, with a median of $259357.5 recorded in 2021.
  • Peak YoY movement for Current Deferred Revenue: surged 2352.96% in 2023, then crashed 98.41% in 2025.
  • A 5-year view of Current Deferred Revenue shows it stood at $266504.0 in 2021, then plummeted by 79.29% to $55180.0 in 2022, then surged by 1933.6% to $1.1 million in 2023, then crashed by 77.52% to $252211.0 in 2024, then plummeted by 95.52% to $11293.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $11293.0 in Q3 2025, $22685.0 in Q2 2025, and $217841.0 in Q1 2025.